CYTOSORBENTS MEDICAL INC — Department of Health and Human Services SBIR Phase I: 300
CYTOSORBENTS MEDICAL INC — SBIR Phase I award from Department of Health and Human Services.
Phase I SBIR feasibility signal
- Phase I awards fund proof-of-concept work. For capture teams, they mark early interest from Department of Health and Human Services in a technical approach.
- Watch for Phase II follow-ons from the same firm/topic family — that conversion path is where budgets and transition pressure rise.
- Obligated amount $288,335. Cross-check similar awards in the same agency and technology tags for going-rate context.
- Topic code 300 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $288,335
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Topic
- 300
- Solicitation
- PA20-272
- NAICS
- —
- Place of performance
- NJ
- Period
- 2022-09-01 → 2023-04-30
Description
PROJECT SUMMARY The funds from this administrative supplement will be utilized for Technical and Business Assistance (TABA). Specifically, we intend to use the funds to cover intellectual property strategy consultation fees to provide us with a sound patent strategy for our novel polymer sorbent LPSorb. Sepsis is an extreme reaction to pathogen infection and is one of the deadliest conditions in the world. The field of sepsis care currently lacks an effective treatment to counteract both the bacterial-derived endotoxins found in certain types of sepsis and the massive cytokine-mediated immune response to the infection that can lead to organ failure and death. LPSorb has demonstrated the potential to be an extremely effective extracorporeal endotoxin adsorber. When coupled with our cytokine adsorber CytoSorb, which is currently on the market, LPSorb should provide a novel and effective therapy for deadly Gram-negative sepsis. The innovative formulation developed by our polymer chemistry team will require intellectual property protection to allow for continued innovation and to provide maximum revenue, enabling the establishment of a viable new product line for the company. To achieve this, we propose to use these supplemental funds to engage our longtime IP counsel BakerHostetler to seek intellectual property counsel to develop a suitable patent strategy which will ultimately enable us to efficiently pursue both material and application patents for this innovative product.